Taiho Pharmaceutical Company Limited

Msd K.k.

Banyu Pharmaceutical Co. Ltd

Takashi Mizutani

Nagaaki Sato

Shuichi Ohkubo

Tsuyoshi Nagase

Makoto Kitade

Chihoko Yoshimura

Hitomi Kondo

Akio Kanatani

Toshiyuki Takahashi

Yoshio Ogino

Shigeru Tokita

Fuyuki Yamamoto

Hidekazu Takahashi

Takahide Sasaki

Shiho Ishikawa

Shoki Hara

Yu Kobayakawa

Hidefumi Kasuga

Hirokazu Fuchida

The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors

A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof. The pyrrolopyrimidine compound or a salt thereof has an NAE inhibitory action and a cell growth inhibitory effect and is represented by Formula (A): 

Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof

[PROBLEMS] To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases. [MEANS FOR SOLVING PROBLEMS] The compound, which is for use as an active ingredient, is represented by the formula (I): [wherein Rrepresents optionally halogenated Calkyl, etc.; Rrepresents, e.g., a group represented by the formula (II-1) or (II-4) (wherein W represents Calkylene, etc. and R represents Calkyl, etc.); Rrepresents hydrogen, Calkyl, etc.; X represents &#x2014;O&#x2014;, &#x2014;NH&#x2014;, etc.; and Y, Y, Y, and Yeach independently represents &#x2014;CH&#x2014;, &#x2014;N&#x2014;, etc.].

Benzoxazinone derivative

Disclosed is a compound represented by the formula (I) below and a pharmaceutically acceptable salt thereof.  This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; Xrepresents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; Xrepresents a group represented by the following formula (II): (wherein Rand Rrespectively represent a lower alkyl group or the like, and m represents a number of 2-4) or the like; one of X and Y represents an oxygen atom and the other represents a sulfanyl group or the like; and X-Xrespectively represent &#x2014;CH&#x2014;, a nitrogen atom or the like. 

Benzoxathiin derivative

This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein Rrepresents a lower alkyl group et al; Rand Rare same and different and represents hydrogen atm et al; Rrepresents the substituent of the formula (II) et al; Xrepresents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

Quinazoline derivative

Growing community of inventors

Moriya, Japan

Takashi Mizutani